54248-88-3Relevant academic research and scientific papers
Facile Synthesis of New [1,2,4]Triazolo[4,3-b]pyridazine
Arghiani,Seyedi,Bakavoli,Eshghi
, p. 1099 - 1107 (2015/08/06)
A number of new [1,2,4]triazolo[4,3-b]pyridazines were prepared by either cyclocondesation of substituted hydrazinopyridazines with orthoesters or oxidative cyclization of their hydrazone analogs in nitrobenzene as an oxidizing agent. A host of other new
Triazolopyridazine LRRK2 kinase inhibitors
Franzini, Maurizio,Ye, Xiaocong M.,Adler, Marc,Aubele, Danielle L.,Garofalo, Albert W.,Gauby, Shawn,Goldbach, Erich,Probst, Gary D.,Quinn, Kevin P.,Santiago, Pam,Sham, Hing L.,Tam, Danny,Truong, Anh,Ren, Zhao
, p. 1967 - 1973 (2013/04/24)
Leucine-rich repeat kinase 2 (LRRK2) has been implicated in the pathogenesis of Parkinson's disease (PD). Inhibition of LRRK2 kinase activity is a therapeutic approach that may lead to new treatments for PD. Herein we report the discovery of a series of [
7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy) -3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine: A functionally selective γ-aminobutyric acidA (GABAA) α2/α3- subtype selective agonist that exhibits potent anxiolyti
Carling, Robert W.,Madin, Andrew,Guiblin, Alec,Russell, Michael G. N.,Moore, Kevin W.,Mitchinson, Andrew,Sohal, Bindi,Pike, Andrew,Cook, Susan M.,Ragan, Ian C.,McKernan, Ruth M.,Quirk, Kathleen,Ferris, Pushpinder,Marshall, George,Thompson, Sally Ann,Wafford, Keith A.,Dawson, Gerard R.,Atack, John R.,Harrison, Timothy,Castro, José L.,Street, Leslie J.
, p. 7089 - 7092 (2007/10/03)
There is increasing evidence that compounds with selectivity for γ-aminobutyric acidA (GABAA) α2- and/or α3-subtypes may retain the desirable anxiolytic activity of nonselective benzodiazepines but possess an improved side effect pro
